PEACCEL and SeSaM-Biotech sign enzyme development collaboration

PEACCEL and SeSaM-Biotech sign enzyme development collaboration

Paris and Aachen, 27th November 2017


Peaccel and SeSaM-Biotech today jointly announced the signature of a collaboration agreement. Under the agreement, Peaccel and SeSaM-Biotech will develop improved enzyme variants of a commercially important enzyme family. These variants will be generated with Peaccel’s proprietary iSAR machine learning technology, which enables the rapid prediction and identification of improved enzyme mutants. SeSaM-Biotech will express and characterize the enzyme variants with its in-house protein expression platforms.

Rudy Pandjaitan, Senior Director of Business Development at Peaccel commented: “This agreement is a perfect match between Peaccel’s machine learning enzyme engineering expertise and SeSaM-Biotech’s enzyme expression capabilities. This collaboration will provide Peaccel a superb opportunity to develop its first commercial product and to establish a second line of business besides its fee-for service contract business. SeSaM-Biotech is the ideal partner for this first project as they not only have a long track record of successful enzyme expression, but also a profound knowledge of the specific enzyme family.”
“Peaccel’s iSAR technology has the potential to drastically shorten protein engineering projects and at the same time yield high performing enzyme variants“, stated David Schönauer, Managing Director of SeSaM-Biotech. “We are excited to join forces with Peaccel and to combine the strengths of both companies. This collaboration allows us to provide even better evolution services for our clients.”


About Peaccel
PEACCEL is a service company specialized in protein engineering and design and synthetic biology. The company provides predictive product discovery solutions to biotech & pharmaceutical companies. Its unique expertise and proprietary machine learning in-silico discovery platform iSAR are dedicated to rapidly identify improved protein variants (enzymes, antibodies, peptides). As iSAR efficiently predicts and identifies proteins with improved properties it reduces the time, costs and risks associated with engineering of protein therapeutics, industrial enzymes and synthetic pathways.


About SeSaM-Biotech
As an ‘all-in-one’ protein engineering service provider, SeSaM-Biotech improves industrial enzymes for all industry sectors that employ enzymes in their products or processes. The track record spans a range of enzymes including amylases, lipases, esterases, cellulases, glucose oxidases, monooxygenases, phytases, proteases, pectinases, polymerases and isomerases which have been improved towards higher activity, thermal resistance and solvent stabilities. With cutting-edge technologies for mutagenesis like SeSaM and OmniChange, diverse expression platforms, computational modelling of enzymes and individually adapted screening assays, SeSaM-Biotech provides tailored Directed Evolution of enzymes to clients across the globe to make their products eco-friendlier, more cost effective and more valuable.


For further information contact:
Rudy Pandjaitan, Senior Director Business Development:
Visit our website:


David Schönauer, Managing Director:
Visit our website: